The invention presents a panel of protein biomarkers for dengue fever (DF) and its severe form, dengue hemorrhagic fever (DHF). These biomarkers aid in predicting disease progression from DF to DHF and assessing severity. The methodology involves analyzing plasma samples from dengue patients, processing them to extract proteins, conducting various proteomic techniques such as 2D-DIGE and LC-MS/MS for identification, and ultimately developing a kit for assessing severity based on the expression levels of these biomarkers. By analyzing plasma samples and employing proteomic techniques, the invention provides a method for early detection and monitoring of dengue severity. This advancement offers potential for improved diagnostics and therapy for dengue patients.
Figure (1) Work flow for comparative proteomic analysis of dengue fever patients at two different time points and healthy controls using a gel-based (2D-DIGE) and gelfree platform (iTRAQ).
Current diagnostic methods such as PCR-based techniques, rapid diagnostic tests (RDTs), and ELISA, focus primarily on identifying the presence of dengue virus or antibodies but do not effectively predict the progression to severe forms of the disease, such as dengue hemorrhagic fever (DHF). The mechanisms underlying the progression from dengue fever (DF) to DHF are not fully understood, highlighting the need for reliable biomarkers that can aid in early identification of patients at risk of developing severe complications. This limitation hampers early intervention and effective management, leading to adverse outcomes.
- Comprehensive Biomarker Panel: The invention provides a robust panel of host protein biomarkers for detecting dengue virus infection, enabling a multi-dimensional diagnostic approach based on specific protein expression patterns.
- Improved Diagnostic Accuracy: Incorporating a diverse range of biomarkers—such as Alpha-1-acid glycoprotein 1 & 2, Apolipoprotein A-II, and Ig Kappa chain C region—significantly enhances the accuracy and reliability of diagnosis.
- Versatile Sample Compatibility: The biomarker panel is compatible with various biological samples, including whole blood, plasma, serum, and tissue biopsy, offering flexibility in clinical settings.
- User-Friendly Diagnostic Kit: The diagnostic kit includes receptacles for blood collection, the biomarker panel, and detailed instructions to assist healthcare professionals in interpreting results based on protein expression levels.
- Targeted Biomarker Utility: Specific proteins such as Plasma protease C1 inhibitor and Haemoglobin subunit alpha further strengthen the diagnostic capability by focusing on key indicators associated with dengue virus infection.
This diagnostic kit prototype requires blood samples collected in standard serum separation tubes. The biomarker panel includes specific reagents or test strips for detecting the expression levels of host protein biomarkers such as Alpha-1- acid glycoprotein 1 & 2 and Hemoglobin subunit alpha. The kit is powered by standard laboratory equipment for analysis, requiring electricity supply (110-240V AC). It utilizes biochemical agents for protein extraction and analysis, including buffers, reducing agents like Tris (2-carboxyethyl) phosphine (TCEP), and labeling reagents such as 4-plex iTRAQ reagent. The dimensions of the prototype are compact, designed for easy handling and storage in healthcare settings. It can process multiple samples simultaneously, with performance metrics including sensitivity, specificity, and turnaround time for results.
Biomarker panel validated on clinical samples using proteomic and cytokine assays. Potential for a diagnostic kit demonstrated. Currently lab-validated and available for licensing.
4
This innovation contributes to society by improving healthcare access, enhancing disease management, reducing the burden on healthcare systems, enabling targeted preventative measures, and providing economic benefits through cost savings and increased productivity.
- Medical diagnostics: Used for the detection and monitoring of dengue virus infections.
- Public health: Enables early identification of severe dengue cases for timely intervention and management.
- Drug development: Provides insights for the development of targeted therapies against dengue virus infection.
- Epidemiological surveillance: Contributes to understanding the prevalence and dynamics of dengue outbreaks.
Geography of IP
Type of IP
201721018611
484073